Literature DB >> 19614792

Pulse pressure and the metabolic syndrome in patients with hypertension.

Vivencio Barrios1, Carlos Escobar, Rocio Echarri, Arantxa Matalí.   

Abstract

The authors examined the clinical profile of the hypertensive population with the metabolic syndrome (MetS) and elevated pulse pressure (PP) in a sample of 5866 patients (3291 women and 2575 men) included in a large hypertension survey performed in primary care setting. Elevated PP was defined as >or=80 mm Hg in women and >or=75 mm Hg in men; 92.7% of women and 87.6% of men had normal PP values. Patients with higher PP levels were older, were more commonly diabetic, and exhibited more frequently target organ damage and associated clinical conditions. Blood pressure was less well controlled in the subgroup of patients with elevated PP: control rates were 4.1% vs 19.2%, P<.001; men, 3.9% vs 19.0%, P<.001; P=NS between sexes. Low-density lipoprotein cholesterol was similarly controlled regardless of PP: control rates were, 17.0% vs 17.8%; in women with high PP vs normal PP and 25.2% vs 25.1% in men with high PP vs normal PP, both P=NS; P<.001 between sexes with high PP. In the patients with high PP, the female subgroup was older, was more obese, and had more left ventricular hypertrophy and fewer associated clinical conditions than did men. The odds ratio of having high PP in women with MetS vs no MetS was 3.13 and in men was 1.9 (both P<.01).

Entities:  

Mesh:

Year:  2009        PMID: 19614792     DOI: 10.1111/j.1559-4572.2008.00041.x

Source DB:  PubMed          Journal:  J Cardiometab Syndr        ISSN: 1559-4564


  2 in total

1.  Cardiac rehabilitation programs improve metabolic parameters in patients with the metabolic syndrome and coronary heart disease.

Authors:  Ignacio P Pérez; Maria A Zapata; Carlos E Cervantes; Rosario M Jarabo; Cristina Grande; Rose Plaza; Sara Garcia; Miriam L Rodriguez; Silvia Crespo; Jesús Perea
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-05       Impact factor: 3.738

Review 2.  Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetes.

Authors:  Margarita SaizSatjes; Francisco Javier Martinez-Martin
Journal:  Drugs Context       Date:  2018-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.